Wink Logan K, Adams Ryan, Pedapati Ernest V, Dominick Kelli C, Fox Emma, Buck Catherine, Erickson Craig A
Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue MLC 4002, Cincinnati, OH, 45229, USA.
J Autism Dev Disord. 2017 Jul;47(7):2290-2294. doi: 10.1007/s10803-017-3132-2.
Antipsychotic treatment in youth with autism spectrum disorder (ASD) is becoming increasingly common, placing individuals at risk for antipsychotic-induced weight gain and associated complications. Metformin hydrochloride, a biguanide medication FDA-approved for treatment of type-2 diabetes in youth, may hold promise for treatment of antipsychotic-induced weight gain in youth with ASD. In this report we assess the long-term impact of metformin on antipsychotic-associated weight gain in a naturalistic sample of 53 youth with ASD. Results indicate that treatment with metformin stabilized BMI z-score over a nearly 2 year mean treatment period. Further work is indicated to determine the safety and efficacy of metformin treatment in youth with ASD, as well as predictors of response as a treatment for antipsychotic-induced weight gain.
在患有自闭症谱系障碍（ASD）的青少年中，抗精神病药物治疗越来越普遍，这使个体面临抗精神病药物导致体重增加及相关并发症的风险。盐酸二甲双胍是一种经美国食品药品监督管理局（FDA）批准用于治疗青少年2型糖尿病的双胍类药物，可能有望用于治疗患有ASD的青少年因抗精神病药物导致的体重增加。在本报告中，我们评估了二甲双胍对53名患有ASD的青少年自然样本中与抗精神病药物相关的体重增加的长期影响。结果表明，在近2年的平均治疗期内，二甲双胍治疗使体重指数（BMI）z评分稳定。需要进一步开展工作以确定二甲双胍治疗患有ASD的青少年的安全性和有效性，以及作为抗精神病药物导致体重增加治疗方法的反应预测因素。
